Year |
Citation |
Score |
2023 |
Goyal Y, Busch GT, Pillai M, Li J, Boe RH, Grody EI, Chelvanambi M, Dardani IP, Emert B, Bodkin N, Braun J, Fingerman D, Kaur A, Jain N, Ravindran PT, et al. Diverse clonal fates emerge upon drug treatment of homogeneous cancer cells. Nature. PMID 37468627 DOI: 10.1038/s41586-023-06342-8 |
0.731 |
|
2023 |
Fane ME, Ecker BL, Kaur A, Marino GE, Alicea GM, Douglass SM, Chhabra Y, Webster MR, Marshall A, Colling R, Espinosa O, Coupe N, Maroo N, Campo L, Middleton MR, et al. Correction: sFRP2 Supersedes VEGF as an Age-related Driver of Angiogenesis in Melanoma, Affecting Response to Anti-VEGF Therapy in Older Patients. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 29: 2012. PMID 37183634 DOI: 10.1158/1078-0432.CCR-23-0871 |
0.545 |
|
2022 |
Dardani I, Emert BL, Goyal Y, Jiang CL, Kaur A, Lee J, Rouhanifard SH, Alicea GM, Fane ME, Xiao M, Herlyn M, Weeraratna AT, Raj A. ClampFISH 2.0 enables rapid, scalable amplified RNA detection in situ. Nature Methods. PMID 36280724 DOI: 10.1038/s41592-022-01653-6 |
0.655 |
|
2020 |
Fane ME, Ecker BL, Kaur A, Marino GE, Alicea GM, Douglass SM, Chhabra Y, Webster MR, Marshall A, Colling R, Espinosa O, Coupe N, Maroo N, Campo L, Middleton MR, et al. sFRP2 Supersedes VEGF as an Age-related Driver of Angiogenesis in Melanoma, Affecting Response to Anti-VEGF Therapy in Older Patients. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 33097493 DOI: 10.1158/1078-0432.CCR-20-0446 |
0.567 |
|
2020 |
Webster MR, Fane ME, Alicea GM, Basu S, Kossenkov AV, Marino GE, Douglass SM, Kaur A, Ecker BL, Gnanapradeepan K, Ndoye A, Kugel C, Valiga A, Palmer J, Liu Q, et al. Paradoxical Role for Wild-Type p53 in Driving Therapy Resistance in Melanoma. Molecular Cell. 77: 681. PMID 32032511 DOI: 10.1016/J.Molcel.2020.01.005 |
0.591 |
|
2019 |
Webster MR, Fane ME, Alicea GM, Basu S, Kossenkov AV, Marino GE, Douglass SM, Kaur A, Ecker BL, Gnanapradeepan K, Ndoye A, Kugel C, Valiga A, Palmer J, Liu Q, et al. Paradoxical Role for Wild-Type p53 in Driving Therapy Resistance in Melanoma. Molecular Cell. PMID 31836388 DOI: 10.1016/J.Molcel.2019.11.009 |
0.639 |
|
2019 |
Rupp C, Isomursu A, Aakula A, Erickson A, Li S, Kaur A, Shah P, Pokharel YR, Trottman L, Lammerding J, Rannikko A, Taimen P, Mirtti T, Paatero I, Ivaska J, et al. Abstract 3486: Combined inhibition of tumor suppressors PTEN and PP2A drives anoikis resistance and is associated with therapy relapse in prostate cancer Cancer Research. 79: 3486-3486. DOI: 10.1158/1538-7445.Am2019-3486 |
0.383 |
|
2018 |
Kaur A, Ecker BL, Douglass SM, Kugel CH, Webster MR, Almeida FV, Somasundaram R, Hayden J, Ban E, Ahmadzadeh H, Franco-Barraza J, Shah N, Mellis IA, Keeney F, Kossenkov A, et al. Remodeling of the collagen matrix in aging skin promotes melanoma metastasis and affects immune cell motility. Cancer Discovery. PMID 30279173 DOI: 10.1158/2159-8290.Cd-18-0193 |
0.686 |
|
2018 |
Ecker BL, Kaur A, Douglass SM, Webster MR, Almeida FV, Marino G, Sinnamon AJ, Neuwirth MG, Alicea GM, Ndoye A, Fane M, Xu X, Sim MS, Deutsch GB, Faries MB, et al. Age-Related Changes in HAPLN1 Increase Lymphatic Permeability and Affect Routes of Melanoma Metastasis. Cancer Discovery. PMID 30279172 DOI: 10.1158/2159-8290.Cd-18-0168 |
0.601 |
|
2018 |
Kugel CH, Douglass SM, Webster MR, Kaur A, Liu Q, Yin X, Weiss SA, Darvishian F, Al-Rohil RN, Ndoye A, Behera R, Alicea GM, Ecker BL, Fane M, Allegrezza MJ, et al. Age Correlates with Response to Anti-PD1, Reflecting Age-Related Differences in Intratumoral Effector and Regulatory T-Cell Populations. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 29898988 DOI: 10.1158/1078-0432.Ccr-18-1116 |
0.589 |
|
2018 |
Webster MR, Fane M, Kaur A, Alicea G, Ecker BL, Ndoye A, Kugel C, Basu S, Valiga A, Appleton JL, Murphy ME, Weeraratna A. Abstract 993: Wnt-er is coming: WNT5A promotes a slow cycling phenotype via p53 in conditions of stress Tumor Biology. DOI: 10.1158/1538-7445.Am2018-993 |
0.525 |
|
2017 |
Ndoye A, Budina-Kolomets A, Kugel CH, Webster MR, Kaur A, Behera R, Rebecca VW, Li L, Brafford PA, Liu Q, Vashisht Gopal YN, Davies MA, Mills GB, Xu X, Wu H, et al. ATG5 mediates a positive feedback loop between Wnt signaling and autophagy in melanoma. Cancer Research. PMID 28887323 DOI: 10.1158/0008-5472.Can-17-0907 |
0.613 |
|
2017 |
Behera R, Kaur A, Webster MR, Kim S, Ndoye A, Kugel CH, Alicea GM, Wang JX, Ghosh K, Cheng PF, Lisanti S, Marchbank K, Dang V, Levesque MP, Dummer R, et al. Inhibition of age-related therapy resistance in melanoma by rosiglitazone-mediated induction of Klotho. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 28232477 DOI: 10.1158/1078-0432.Ccr-17-0201 |
0.663 |
|
2017 |
Webster MR, Kaur A, Ndoye A, Kugel C, Basu S, Valiga A, Appleton J, Wang Y, Murphy M, Weeraratna AT. Abstract 4913: Invasive melanoma cells commandeer p53 activity to promote the survival of a therapy resistant subpopulation Cancer Research. 77: 4913-4913. DOI: 10.1158/1538-7445.Am2017-4913 |
0.429 |
|
2016 |
Kaur A, Westermarck J. Regulation of protein phosphatase 2A (PP2A) tumor suppressor function by PME-1. Biochemical Society Transactions. 44: 1683-1693. PMID 27913678 DOI: 10.1042/Bst20160161 |
0.332 |
|
2016 |
Kaur A, Webster MR, Weeraratna AT. In the Wnt-er of life: Wnt signalling in melanoma and ageing. British Journal of Cancer. PMID 27764844 DOI: 10.1038/Bjc.2016.332 |
0.614 |
|
2016 |
Kaur A, Denisova O, Qiao X, Jumppanen M, Peuhu E, Ahmed SU, Raheem O, Haapasalo HK, Eriksson J, Chalmers AJ, Laakkonen PM, Westermarck J. PP2A inhibitor PME-1 drives kinase inhibitor resistance in glioma cells. Cancer Research. PMID 27671680 DOI: 10.1158/0008-5472.Can-16-1134 |
0.357 |
|
2016 |
Kaur A, Webster MR, Marchbank K, Behera R, Ndoye A, Kugel CH, Dang VM, Appleton J, O'Connell MP, Cheng P, Valiga AA, Morissette R, McDonnell NB, Ferrucci L, Kossenkov AV, et al. Corrigendum: sFRP2 in the aged microenvironment drives melanoma metastasis and therapy resistance. Nature. PMID 27383789 DOI: 10.1038/Nature18939 |
0.583 |
|
2016 |
Kaur A, Webster MR, Marchbank K, Behera R, Ndoye A, Kugel CH, Dang VM, Appleton J, O'Connell MP, Cheng P, Valiga AA, Morissette R, McDonnell NB, Ferrucci L, Kossenkov AV, et al. sFRP2 in the aged microenvironment drives melanoma metastasis and therapy resistance. Nature. PMID 27042933 DOI: 10.1038/Nature17392 |
0.67 |
|
2015 |
Kaur A, Elzagheid A, Birkman EM, Avoranta T, Kytölä V, Korkeila E, Syrjänen K, Westermarck J, Sundström J. Protein phosphatase methylesterase-1 (PME-1) expression predicts a favorable clinical outcome in colorectal cancer. Cancer Medicine. PMID 26377365 DOI: 10.1002/Cam4.541 |
0.321 |
|
2015 |
Webster MR, Xu M, Kinzler KA, Kaur A, Appleton J, O'Connell MP, Marchbank K, Valiga A, Dang VM, Perego M, Zhang G, Slipicevic A, Keeney F, Lehrmann E, Wood W, et al. Wnt5A promotes an adaptive, senescent-like stress response, while continuing to drive invasion in melanoma cells. Pigment Cell & Melanoma Research. 28: 184-95. PMID 25407936 DOI: 10.1111/Pcmr.12330 |
0.629 |
|
2015 |
Webster MR, Xu M, Kinzler K, Kaur A, Appleton J, O'Connell MP, Marchbank K, Valiga A, Dang V, Perego M, Zhang G, Slipicevic A, Keeney F, Lehrmann E, Wood W, et al. Abstract B27: Wnt5A-expressing melanoma cells show classical markers of senescence following radiation and therapeutic stress, but retain the ability to metastasize and proliferate at distant sites Cancer Research. 75. DOI: 10.1158/1538-7445.Mel2014-B27 |
0.303 |
|
2015 |
Behera R, Marchbank K, Kaur A, Dang V, Webster M, O'Connell M, Xu X, Weeraratna A. Abstract A11: Crosstalk between klotho and wnt5A drives age-related melanoma progression Cancer Research. 75. DOI: 10.1158/1538-7445.Mel2014-A11 |
0.635 |
|
2015 |
Kaur A, Marchbank K, Dang V, O'Connell M, Webster M, Appleton J, Cheng P, Valiga A, Morissette R, McDonnell N, Ferrucci L, Kossenkov A, Meeth K, Bosenberg M, Tang H, et al. Abstract A04: Aging microenvironment modulates melanoma invasion and metastasis Cancer Research. 75. DOI: 10.1158/1538-7445.Mel2014-A04 |
0.652 |
|
2015 |
Kauko O, Imanishi S, Kaur A, Laajala D, Kulesskiy E, Jumppanen M, Corthals G, Aittokallio T, Wennerberg K, Westermarck J. Abstract 5328: Protein phosphatase 2A activity is a major determinant of therapy response in cancer cells Cancer Research. 75: 5328-5328. DOI: 10.1158/1538-7445.Am2015-5328 |
0.368 |
|
2015 |
Kaur A, O'Connell M, Webster M, Behera R, Dang V, Ndoye A, Weeraratna A. Abstract 5092: Midkine as a potential target for combating drug resistance and invasion in melanoma Cancer Research. 75: 5092-5092. DOI: 10.1158/1538-7445.Am2015-5092 |
0.645 |
|
2015 |
Webster MR, Basu S, Kaur A, Appleton J, Murphy ME, Weeraratna AT. Abstract 3775: p53 is differentially regulated in proliferative and invasive melanoma cells Cancer Research. 75: 3775-3775. DOI: 10.1158/1538-7445.Am2015-3775 |
0.327 |
|
2015 |
Ndoye A, Budina A, Webster M, Kaur A, Behera R, Murphy M, Weeraratna AT. Abstract 2906: Role of autophagy in Wnt5A-mediated melanoma invasion and metastasis Cancer Research. 75: 2906-2906. DOI: 10.1158/1538-7445.Am2015-2906 |
0.403 |
|
2015 |
Behera R, Kaur A, Marchbank K, Dang V, Webster M, Xu X, Weeraratna AT. Abstract 1556: Role of Klotho in age-related melanoma progression Cancer Research. 75: 1556-1556. DOI: 10.1158/1538-7445.Am2015-1556 |
0.431 |
|
2014 |
Sekulic A, Weeraratna AT, MacKeigan JL, Kaur A, O'Connell M, Goodall ML, Barrett M, Lenkiewitz E, Holley T, Zismann V, Gordon M, Bollag G, Zhang C, Trent JM. Abstract LB-213: Discovery and molecular modeling of a novel mutation in the vemurafenib binding site of BRAF associated with therapeutic resistance in a patient with metastatic melanoma Cancer Research. 74. DOI: 10.1158/1538-7445.Am2014-Lb-213 |
0.377 |
|
2013 |
O'Connell MP, Marchbank K, Webster MR, Valiga AA, Kaur A, Vultur A, Li L, Herlyn M, Villanueva J, Liu Q, Yin X, Widura S, Nelson J, Ruiz N, Camilli TC, et al. Hypoxia induces phenotypic plasticity and therapy resistance in melanoma via the tyrosine kinase receptors ROR1 and ROR2. Cancer Discovery. 3: 1378-93. PMID 24104062 DOI: 10.1158/2159-8290.Cd-13-0005 |
0.644 |
|
2013 |
Westermarck J, Kaur A. Abstract A97: PPME1 is a novel target for synthetic lethal therapy in human gliomas. Molecular Cancer Therapeutics. 12. DOI: 10.1158/1535-7163.Targ-13-A97 |
0.387 |
|
2012 |
Kaur A, Cvrljevic A, Westermarck J. Abstract B36: Re-activation of protein phosphatase 2A as a multi-target strategy for combating chemotherapy resistance of common cancer types Clinical Cancer Research. 18. DOI: 10.1158/1078-0432.Mechres-B36 |
0.368 |
|
Show low-probability matches. |